

ASX/Media Release

27 June 2019

Media interview with Botanix President

Key highlights

- **Video interview with Botanix President, Vince Ippolito, has been released, following the recent release of the Phase 1b BTX 1308 interim result and the antimicrobial data**
- **Mr Ippolito discusses the clinical and commercial importance of the results and opportunities in global medical dermatology**

Philadelphia PA and Sydney Australia, 27 June 2019: Clinical stage cannabinoid company Botanix Pharmaceuticals (“Botanix” or “the Company”) is pleased to advise that Vince Ippolito, Botanix President, was recently interviewed by the Finance News Network.

During the interview, Mr Ippolito provides details on his extensive experience in medical dermatology. The interview also highlights the clinical and commercial importance of Botanix’s BTX 1308 mechanism of action data and BTX 1801 antimicrobial data. The interview is now available on the Company’s website: <https://www.botanixpharma.com/investors/>

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of cannabidiol. Treatment targets include inflammation, deterioration of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis. Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical study in June 2018 with study completion expected in 3Q CY2019. The BTX 1204 atopic dermatitis Phase 2 patient study is also underway with study completion expected in 4Q CY2019. Finally, Phase 1b BTX 1308 psoriasis mechanism of action study has recently completed, with positive interim data announced in June 2019. Pipeline developments that leverage the antimicrobial properties of cannabidiol are also moving forward and are planned to enter the clinic in 2H CY2019.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals
Founder & Executive Director

+1 215 767 4184

mcallahan@botanixpharma.com

Investor enquiries

Joel Seah
Vesparum Capital

P: +61 3 8582 4800

botanixpharma@vesparum.com

Media enquiries

Haley Chartres
Hales² Consultancy

P: +61 423 139 163

haley@h-squared.com.au